Dabur India Limited Chief Executive Officer Mohit Malhotra said We entered this crisis from a position of strength. We were growing at a steady pace when the COVID pandemic brought business to a standstill. Amidst this challenging business environment, we quickly revamped our portfolio to meet the growing consumer need for quality Preventive Healthcare, Personal Hygiene and Household Hygiene products, while alongside enhancing the production of our existing Ayurvedic Immunity boosters like Dabur Chyawanprash and Dabur Honey.”
Malhotra further said, “Despite a challenging April, the quarter saw a nearly 7-fold growth in demand for Dabur Chyawanprash and an over 60% surge in demand for Dabur Honey. Dabur has significantly ramped up capacity with production now at near-normal levels and the business poised to deliver growth for the rest of the year.”
In the quarter, Dabur Chyawanprash reported a growth of over 694% during the quarter, while Dabur Honitus grew by over 80% and Dabur Honey ended Q1 2020-21 with a growth of over 60%. The quarter saw Dabur introduce a record number of new products and variants anchored on the consumer need for Health, Immunity and Hygiene. The quarter saw our new products record Sales of over Rs100cr.
On Sensex, Dabur stock ended at Rs513.45 per piece higher by 4.23%.
